This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

M. Armoni, MD; M. Schlesinger, MD; P. A. Vardy, MD; A. Metzker, MD
Department of Pediatrics Barzilai Medical Center, Ashkelon, Israel; Pediatric Dermatology Unit Beilinson Medical Center Petah Tiqva, Israel

Arch Dermatol. 1985;121(2):168-169.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

We read with great interest the article by Rogers et al¹ on the use of phenytoin in the treatment of junctional epidermolysis bullosa (JEB).

We are in complete agreement with the authors regarding the value of this drug in treating JEB and recessive dystrophic epidermolysis bullosa (RDEB), but we have certain reservations about the dosage recommended.

About a year ago we used phenytoin to treat an infant suffering from RDEB; because of the severity of his condition, we started with a full anticonvulsive dose of 7 mg/kg/day that resulted in complete recovery of all his bullae within ten days.

It is our impression from reading the aforementioned article,¹ as well as that in which Bauer et al² recorded a large series of phenytoin-treated cases, that they were reluctant to start with full doses because of the possibility of side effects.

As pediatricians, we are convinced . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?